Focused On-demand Library for N-alpha-acetyltransferase 10

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P41227

UPID:
NAA10_HUMAN

ALTERNATIVE NAMES:
N-terminal acetyltransferase complex ARD1 subunit homolog A; NatA catalytic subunit Naa10

ALTERNATIVE UPACC:
P41227; A6NM98

BACKGROUND:
The protein N-alpha-acetyltransferase 10, alternatively named NatA catalytic subunit Naa10, is integral to post-translational modification of proteins. It acetylates the N-termini of proteins lacking initiator methionine, a process essential for proper protein function and stability. Naa10's activity influences various cellular pathways, including those related to tumor suppression and heat shock response, by acetylating and regulating the function of proteins such as HIF1A, MYLK, and HSPA1B.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of N-alpha-acetyltransferase 10 could open doors to potential therapeutic strategies. Its direct association with genetic disorders like N-terminal acetyltransferase deficiency and Microphthalmia, syndromic, 1, highlights its importance in human health. Targeting Naa10's acetylation activity offers a promising avenue for treating these and potentially other related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.